Short-course therapy for catheter-associated Staphylococcus aureus bacteremia

Area of Science:

• Infectious Diseases
• Clinical Microbiology
• Pharmacology

Background:

• Catheter-associated bacteremia (CAB) caused by Staphylococcus aureus presents a significant clinical challenge.
• Standard treatment durations for S. aureus bacteremia are often lengthy, raising questions about the necessity of prolonged therapy.

Purpose of the Study:

• To evaluate the efficacy and relapse rates of short-course antibiotic therapy (less than 17 days) for patients with S. aureus CAB.
• To identify potential predictors of relapse following short-course treatment.

Main Methods:

• Prospective follow-up of 13 patients with S. aureus CAB who received short-course therapy.
• Minimum three-month follow-up post-therapy to monitor for relapses.
• Literature review to contextualize findings within existing evidence.

Main Results:

• A low relapse rate of 5%–10% was observed in the study and literature review.
• One patient relapsed 28 days post-therapy with endocarditis.
• No identifiable clinical or microbiological predictors of relapse were found.
• Coexistent immunosuppressive conditions did not appear to increase relapse risk.

Conclusions:

• Short-course therapy is a reasonable and effective treatment option for uncomplicated S. aureus CAB.
• Endocarditis is the most common form of relapse and typically occurs within ten weeks of therapy completion.
• Close patient monitoring during the ten weeks post-therapy is crucial for early detection of relapses.